Globus Medical and NuVasive to Sponsor and Participate at EUROSPINE 2023
September 27 2023 - 7:00AM
Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal
solutions company, today announced it will continue its partnership
with EUROSPINE as a silver sponsor and will attend EUROSPINE 2023
held October 4 to 6 in Frankfurt.
“As leaders in the musculoskeletal device industry, we are
committed to procedurally integrated innovation that enables
surgeons to deliver more intelligent surgery,” said Dan
Scavilla, chief executive officer at Globus Medical. “Our
support of EUROSPINE reflects our belief in partnering with the
most influential societies, study groups, and congresses around the
globe to advance spine care and change the lives of more
patients.”
Globus Medical and NuVasive will be hosting various activities
at their respective stands in the Messe Frankfurt exhibition
hall:
- Globus Medical invites attendees to meet the experts at stand
#E35 and learn about Excelsius™ Prone Lateral, ExcelsiusGPS®, and
MARVEL™. On October 5 at 12:00, listen to Dr. David L. Skaggs and
Dr. Michele Federico Pecoraro discuss their clinical experience in
an industry workshop, Robotic Navigation: A discussion on advanced
technology for complex procedures.
- NuVasive invites attendees to meet the experts at stand #E45:
Simplify Cervical Disc with Prof. Dr. med. Steffen K. Rosahl
on October 4 at 10:15 and 15:30, Pulse and X360 with Mr. Andrew
Young on October 5 at 10:15 and 15:30, and Reline 3D with Dr. med.
Lorenz Wanke-Jellinek on October 6 at 10:15.
Surgeons will also have the opportunity for demonstrations of
procedural solutions with ExcelsiusGPS at the Globus Medical stand,
and Pulse and Siemens Healthineers’ Cios Spin at the NuVasive
stand. For more information, please visit the Globus Medical
EUROSPINE webpage and the NuVasive EUROSPINE webpage.
The Company will be exhibiting its musculoskeletal procedural
solutions at various fourth-quarter 2023 conferences,
including:
- Society for Minimally Invasive Spine Surgery (SMISS) ’23 Annual
Forum: October 5 to 7 in Las Vegas.
- North American Spine Society (NASS) 38th Annual Meeting:
October 18 to 21 in Los Angeles.
- 17th International Congress on Early Onset Scoliosis (ICEOS):
November 8 to 10 in Charleston.
- German Spine Congress (DWG) 18th Annual Meeting of the German
Spine Society: November 29 to December 1 in
Stuttgart/Ludwigsburg.
- Cervical Spine Research Society (CSRS) 51st Annual Meeting:
November 29 to December 2 in Las Vegas.
- 9th Annual International Spinal Deformity Symposium (ISDS):
December 1 to 2 in New York.
- International Pediatric Orthopedic Symposium (IPOS): December 5
to 9 in Orlando.
About Globus Medical, Inc.Globus Medical is
committed to providing innovative technologies and industry-leading
clinical support to help surgeons and healthcare providers deliver
better care around the globe. The Company provides one of the most
comprehensive offerings of musculoskeletal solutions and enabling
technologies to impact the care continuum, now including the
procedurally integrated portfolio of NuVasive. The Company’s
employees are relentlessly focused on advancing patient care. For
more information, please visit www.globusmedical.com/uniting.
Safe Harbor StatementsAll statements included
in this press release other than statements of historical fact are
forward-looking statements and may be identified by their use of
words such as “believe,” “may,” “might,” “could,” “will,” “aim,”
“estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan”
and other similar terms. These forward-looking statements are based
on our current assumptions, expectations and estimates of future
events and trends. Forward-looking statements are only predictions
and are subject to many risks, uncertainties and other factors that
may affect our businesses and operations and could cause actual
results to differ materially from those predicted. These risks and
uncertainties include, but are not limited to, the risks and
costs associated with the integration of, and the ability of Globus
Medical and NuVasive to integrate, their businesses successfully
and to achieve anticipated synergies, health epidemics, pandemics
and similar outbreaks, including the COVID-19
pandemic, factors affecting our quarterly results, our ability
to manage our growth, our ability to sustain
our profitability, demand for our products, our ability to
compete successfully (including without limitation our ability to
convince surgeons to use our products and our ability to attract
and retain sales and other personnel), our ability to rapidly
develop and introduce new products, our ability to develop and
execute on successful business strategies, our ability to comply
with laws and regulations that are or may
become applicable to our businesses, our ability to safeguard
our intellectual property, our success in defending legal
proceedings brought against us, trends in the medical device
industry, general economic conditions, and other risks. For a
discussion of these and other risks, uncertainties and other
factors that could affect our results, you should refer to the
disclosure contained in our most recent annual report on Form 10-K
filed with the Securities and Exchange Commission, including the
sections labeled “Risk Factors” and “Cautionary Note Concerning
Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and
other filings with the Securities and Exchange Commission. These
documents are available at www.sec.gov. Moreover, we operate
in an evolving environment. New risk factors and uncertainties
emerge from time to time and it is not possible for us to predict
all risk factors and uncertainties, nor can we assess the impact of
all factors on our business or the extent to which any
factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on any forward-looking
statements. Forward-looking statements contained in this press
release speak only as of the date of this press release. We
undertake no obligation to update any forward-looking statements as
a result of new information, events or circumstances or other
factors arising or coming to our attention after the date
hereof.
Investor contact:Brian
Kearns610-930-1800investors@globusmedical.com
Media contact:Melanie
Ordoñez858-722-3899media@globusmedical.com
Globus Medical (NYSE:GMED)
Historical Stock Chart
From Apr 2024 to May 2024
Globus Medical (NYSE:GMED)
Historical Stock Chart
From May 2023 to May 2024